Morishita Jintan Co., Ltd. operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Morishita Jintan Co., Ltd. with three other
companies in this sector in JAPAN :
Linical Company Limited
sales of 10.94 billion Japanese Yen [US$104.43 million]
of which 91%
was Cro Business),
Shin Nippon Biomedical Laboratories Ltd
(14.56 billion Japanese Yen [US$139.06 million]
of which 90%
was Pre-Clinical Business), and
Japan Tissue Engineering Company Limited
(2.31 billion Japanese Yen [US$22.06 million]
of which 59%
was Regenerative Medicine Products Business).
Morishita Jintan Co., Ltd. reported sales of ¥9.77 billion (US$93.34 million)
March of 2020.
decrease of 3.1%
versus 2019, when the company's sales were ¥10.09 billion.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Morishita Jintan Co., Ltd. had sales
of ¥9.82 billion.
Contributing to the drop in overall sales was the 7.3% decline
in Capsule Contract Business, from ¥2.58 billion to ¥2.39 billion.
There were also decreases in sales in
Healthcare Business (down 2.6% to ¥7.30 billion)
However, these declines were partially offset by the increase in sales of
Other (up 722.2% to ¥74.00 million)